New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
US-2017333576-A1 · Nov 23, 2017 · US
Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US11911488B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11911488-B2 |
| Application number | US-202016984415-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 4, 2020 |
| Priority date | Oct 22, 2014 |
| Publication date | Feb 27, 2024 |
| Grant date | Feb 27, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
First claim
Opening claim text (preview).
That which is claimed: 1. A compound of formula (Ia′): wherein: W is selected from H and F; and Z is selected from Br, F, I, 125 I and 18 F. 2. The compound of claim 1 , wherein Z is selected from Br, I, and F. 3. The compound of claim 1 , wherein Z is selected from 18 F and 125 I. 4. The compound of claim 1 , wherein the compound of formula (Ia′) is selected from:
Assignees
Inventors
Classifications
- A61K51/0402Primary
carboxylic acid carriers, fatty acids (amino acids A61K51/0406) · CPC title
Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent · CPC title
General or multifunctional contrast agents, e.g. chelated agents · CPC title
the fluorescent group being a small organic molecule · CPC title
Methine dyes, e.g. cyanine dyes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11911488B2 cover?
- Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
- Who is the assignee on this patent?
- Univ Johns Hopkins, The Johns Hopkins Universty
- What technology area does this patent fall under?
- Primary CPC classification A61K51/0402. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).